Patients with COVID-19 and RA have increased levels of angiotensin II, which, by decreasing the expression of angiotensin-converting enzyme 2 (ACE2), also leads to reduced vascular permeability and the possibility of lung injury. This evidence concerns the gene ACE2 and COVID-19.